An FDA advisory panel will be reviewing tivozanib on Thursday. Frankly, I'm surprised at the ferocity of selling in Aveo this morning.
http://www.thestreet.com/story/11909243/1/should-aveo-run-second-study-of-kidney-cancer-drug-fda-asks.html
http://www.thestreet.com/story/11909243/1/should-aveo-run-second-study-of-kidney-cancer-drug-fda-asks.html
No comments:
Post a Comment